{
    "ticker": "AACT.WS",
    "name": "Alder BioPharmaceuticals, Inc.",
    "description": "Alder BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for the treatment of migraine and other neurological conditions. Founded in 2002, Alder is dedicated to improving the quality of life for patients suffering from chronic pain through its novel biologic therapies. The company's lead product candidate, eptinezumab, is an intravenous monoclonal antibody designed to prevent migraine episodes by targeting the calcitonin gene-related peptide (CGRP), a key player in migraine pathophysiology. Alder has made significant strides in advancing eptinezumab through clinical trials, demonstrating its efficacy and safety profile, which has positioned the company as a leader in the emerging field of migraine prevention. In addition to its lead product, Alder is exploring a pipeline of other therapeutic candidates aimed at addressing unmet needs in neurology. The company is committed to rigorous research and development, leveraging state-of-the-art technology and collaboration with leading experts in the field to bring groundbreaking treatments to market. Alder BioPharmaceuticals strives to enhance patient outcomes and provide solutions for those affected by debilitating neurological disorders.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Bothell, Washington, USA",
    "founded": "2002",
    "website": "https://www.alderbio.com",
    "ceo": "Randall C. Schatzman",
    "social_media": {
        "twitter": "https://twitter.com/AlderBio",
        "linkedin": "https://www.linkedin.com/company/alder-biopharmaceuticals"
    },
    "investor_relations": "https://investors.alderbio.com",
    "key_executives": [
        {
            "name": "Randall C. Schatzman",
            "position": "CEO"
        },
        {
            "name": "Robert J. Mendez",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "Eptinezumab"
            ]
        }
    ],
    "seo": {
        "meta_title": "Alder BioPharmaceuticals, Inc. | Innovative Migraine Therapies",
        "meta_description": "Alder BioPharmaceuticals is dedicated to developing innovative therapies for migraine and neurological conditions. Learn more about our mission and pipeline.",
        "keywords": [
            "Alder BioPharmaceuticals",
            "Eptinezumab",
            "Migraine Treatment",
            "Neurology",
            "Biopharmaceuticals"
        ]
    },
    "faq": [
        {
            "question": "What is Alder BioPharmaceuticals known for?",
            "answer": "Alder BioPharmaceuticals is known for developing innovative therapies for migraine prevention and other neurological conditions."
        },
        {
            "question": "Who is the CEO of Alder BioPharmaceuticals?",
            "answer": "Randall C. Schatzman is the CEO of Alder BioPharmaceuticals, Inc."
        },
        {
            "question": "Where is Alder BioPharmaceuticals headquartered?",
            "answer": "Alder BioPharmaceuticals is headquartered in Bothell, Washington, USA."
        },
        {
            "question": "What is Alder's lead product candidate?",
            "answer": "Alder's lead product candidate is eptinezumab, an intravenous therapy for migraine prevention."
        },
        {
            "question": "When was Alder BioPharmaceuticals founded?",
            "answer": "Alder BioPharmaceuticals was founded in 2002."
        }
    ],
    "competitors": [
        "AMGN",
        "ABBV",
        "VRNA"
    ],
    "related_stocks": [
        "BIIB",
        "REGN",
        "GILD",
        "VRTX"
    ]
}